{Reference Type}: Journal Article
{Title}: Biodistribution Study of Intravenously Injected Cetuximab-IRDye700DX in Cynomolgus Macaques.
{Author}: de Boer E;Samuel S;French DN;Warram JM;Schoeb TR;Rosenthal EL;Zinn KR;
{Journal}: Mol Imaging Biol
{Volume}: 18
{Issue}: 2
{Year}: Apr 2016
{Factor}: 3.484
{DOI}: 10.1007/s11307-015-0892-y
{Abstract}: <B>OBJECTIVE: </B>The use of receptor-targeted antibodies conjugated to photosensitizers is actively being explored to enhance treatment efficacy. To facilitate clinical testing, we evaluated cetuximab conjugated to IRDye700DX (IR700) in cynomolgus macaques.<BR><B>METHODS: </B>Total IR700 and intact cetuximab-IR700 were measured in 51 tissues at 2 and 14 days after intravenous injection of 40 and 80 mg/kg cetuximab-IR700, respectively, and compared with an unlabeled cetuximab-dosed control group (two each per sex per time point per group).<BR><B>RESULTS: </B>The IR700 retrieved from all tissues at 2 and 14 days after dosing was estimated at 34.9 ± 1.8 and 2.53 ± 0.67% of the total dose, respectively. The tissues with the highest levels of intact cetuximab-IR700 at 2 days after dosing were the blood, lung, and skin. Formalin-fixed paraffin-embedded tissue sections at 2 days after dosing showed the highest IR700 signals in the axillary lymph node, mammary gland, and gall bladder.<BR><B>CONCLUSIONS: </B>Both IR700 and intact cetuximab-IR700 biodistributions were consistent with known epidermal growth factor receptor (EGFR) expression, and changes between 2 and 14 days were consistent with rapid metabolism and excretion of the cetuximab-IR700.